Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification and Validation of RELN Mutation as a Response Indicator for Immune Checkpoint Inhibitor Therapy in Melanoma and Non-Small Cell Lung Cancer.

Cells - 30 Nov 2022

Li Zhenpeng, Wang Xin, Yang Yi, Shi Fuyan, Zhang Wenjing, Wang Qinghua, Wang Suzhen

Abstract excerpt

Remarkable clinical benefits in several advanced cancers are observed under the treatment of immune checkpoint inhibitor (ICI) agents. However, only a smaller proportion of patients respond to the treatments. Reelin (RELN) is frequently mutated in the cancer genome. In this study, the RELN mutation association with ICI treatment efficacy in melanoma and non-small cell lung cancer (NSCLC) was elucidated. Data from...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Immune Checkpoint Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Melanoma

Share to Mutation

Share to Reelin Protein

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 36497098
DOI: 10.3390/cells11233841
PMCID: PMC9741468

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification and Validation of RELN Mutation as a Response Indicator for Immune Checkpoint Inhibitor Therapy in Melanoma and Non-Small Cell Lung Cancer.PMID 36497098Read ↗

Association of EYS mutations with immune checkpoint inhibitor outcome and response in melanoma and non-small cell lung cancerSemantic proximity Read ↗

Clinical Impact of Immune Checkpoint Inhibitor (ICI) Response, DNA Damage Repair (DDR) Gene Mutations and Immune-Cell Infiltration in Metastatic Melanoma Subtypes.Semantic proximity Read ↗

SETBP1 mutation determines sensitivity to immune checkpoint inhibitors in melanoma and NSCLC.Semantic proximity Read ↗

Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma.Semantic proximity Read ↗

Genomic and transcriptomic analyses of melanoma in Japanese patients reveal candidate biomarkers for immune checkpoint inhibitor respondersSemantic proximity Read ↗

RPTOR mutation: a novel predictor of efficacious immunotherapy in melanoma.Semantic proximity Read ↗

A mutational signature and significantly mutated driver genes associated with immune checkpoint inhibitor response across multiple cancers.Semantic proximity Read ↗

Molecular Profiling of Core Immune-Escape Genes Highlights LCK Has Potential to Reshape TME in MelanomaSemantic proximity Read ↗

Predictive value of ZFHX4 mutation for the efficacy of immune checkpoint inhibitors in non-small cell lung cancer and melanoma.Semantic proximity Read ↗

<i>ZNF180</i> modulates tumor intrinsic immunotherapy resistance in melanoma through driving plasticitySemantic proximity Read ↗

NLRP13 mutation as a predictive indicator for immune checkpoint inhibitor efficacy in melanoma and NSCLCSemantic proximity Read ↗

Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.